Veloxis

ENVARSUS XR

Manufacturer:

Veloxis

Envarsus Xr HCPCS:

J7503

HCPCS Code Descriptor:

Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg

Category:

J Code

Envarsus Xr NDCs:

68992-3040-01, 68992-3040-03, 68992-3010-01, 68992-3075-01, 68992-3010-03, 68992-3075-03

Primary Type:

Immunosuppressant

Generic/Specialty Status:

Single-Source

Route of Administration:

Oral

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Envarsus Xr:

ENVARSUS XR is an Immunosuppressant drug manufactured by Veloxis and administered via the Oral route of administration. The J Code: J7503 is aligned to the drug ENVARSUS XR.

Envarsus XR belongs to a class of drugs called immunosuppressants. Envarsus XR is often prescribed to patients who have undergone a kidney transplant. Envarsus XR is thought to work by weakening the body's immune response, which helps the body accept the new organ. Envarsus XR is given orally in tablet form to patients as an anti-rejection drug after a transplant.

ACCESS PRICING AND MORE BY REGISTERING

J7503 Added Date:

January 1, 2016

J7503 Effective Date:

January 1, 2019

J7503 Termination Date:

HCPCS Active

Envarsus Xr billing and coding information can be found through Veloxis at the link below:
Envarsus Xr patient assistance information can be found through Veloxis Pharmaceuticals Patient Support at the URL: http://www.envarsusxr.com/
ENVARSUS XR prescribing information can be found at the link below:
Information regarding ENVARSUS XR’s side effects can be found at MedlinePlus